Accumulating evidences have shown that diabetes upregulated the function and expression of CYP3A4, but the mechanism remained unclear. In this study, HepG2 cells were incubated with serum from diabetic rats induced by streptozotocin, and the activity of CYP3A4 was measured by substrate metabolism. Results showed that incubation with diabetic serum significantly induced CYP3A4 activity in HepG2 cells. To identify the specific factors contribut ing to the regulation, the abnormally altered components in diabetic serum, including glucose, insulin, cholesterol, and free fatty acids were screened. It was found that only fatty acids concen trationdependently upregulated CYP3A4 activity, and the induction by fatty acids was further confirmed in Fa2N4 cells. Data from western blotting and QTPCR showed that induction of CYP3A4 activity was associated with upregulation of CYP3A4 protein and mRNA levels. In addition, effects of pharmacological inhibitors on fatty acid-induced CYP3A4 activity were studied. The results indicated that the induction of CYP3A4 activity by oleic acid may be partly via AMPK, PKC, and NFkB-dependent pathways, whereas that by palmitic acid was possibly associated with the PKCdependent pathway. In conclusion, the increased levels of fatty acids may be one of the reasons leading to the elevated function and expression of CYP3A4 under diabetic conditions.
Introduction
Accumulated evidences have demonstrated that dia betes mellitus markedly alters the activity and expression of cytochromes P450 (CYP450) enzymes (1 -4) . In diabetic rats, the expressions of CYP1A1, 1A2, 2C12, 2E1, and 3A1/2 were apparently increased, while those of CYP2C11, 2C13, and 2A2 were suppressed (2 -5) . Our previous study also demonstrated that the expression and activity of hepatic CYP3A were upregulated in diabetic rats induced by a high dose of streptozotocin (STZ) (model of type 1 diabetes) (6) as well as diabetic rats induced by combination of highfat diet followed by a low dose of STZ (model of type 2 diabetes) (7) .
It is generally accepted that diabetes is associated with insulin deficiency or insulin resistance. Several reports have showed that insulin treatment may reverse altera tion in drugmetabolizing enzyme activity and expres sion induced by diabetes (5, 8) , inferring contribution of insulin to alteration in CYP450 activity and expression under diabetic conditions. Other factors such as testo sterone, tetraiodothyronine (8) , and ketone body (9) were reported to be involved in regulation of CYP450 activity in diabetes mellitus. However, the mechanism leading to the alteration in hepatic CYP3A under the diabetic
HepG2 cell and Fa2N-4 cell culture
HepG2 cells were obtained from the American Type Culture Collection and cultured in DMEM (25 mM glucose) supplemented with 100 mg/ml penicillin, 100 U/ml streptomycin, 2.5 mM lglutamine, 3.7 g/L NaHCO 3 , 1% nonessential amino acids, and 10% fetal bovine serum at 37°C in a humidified atmosphere of 95% air and 5% CO 2 . Medium was changed every other day. When growing to 80% confluence, the HepG2 cells were seeded in 24well plastic plates.
Fa2N4 cell culture of immortalized hepatocytes was performed by the method previously described (11) . In brief, Fa2N4 cells were plated in collagencoated 24well plates (0.67 × 10 6 cells/well, 0.5 mL/well). Cells were maintained at 37°C with 5% CO 2 and 95% relative humidity. After cell attachment (approximately 3h), MFE plating medium was replaced with MFE supporting medium containing supplement A and the cells were cultured for 2 days before treatment.
Assay of CYP3A4 activity in cells
It is wellknown that both Ndealkylation of verapamil (6) and 1′-hydroxylation of midazolam (12) were mainly mediated by CYP3A4. The formations of both norvera pamil and 1′-hydroxylmidazolam were used as the marker to assess CYP3A4 activity. Briefly, the cultured cells were washed once using Hanks' balanced salt solution (HBSS, pH 7.4) and incubated with 100 mM verapamil or 50 mM midazolam at 37°C for 120 min. The incubation media were collected for assaying norverapamil and 1′-hydroxymidazolam. The amounts of norverapamil and 1′-hydroxymidazolam were measured by HPLC (6) or LCMS (12) .
The cells were further lysed by 3 freezethaw cycles and protein concentrations were measured by the Bradford method using BSA as the standard (13) . En zyme activities were expressed as pmol metabolite·min 
Effect of diabetic rat serum on CYP3A4 activity in HepG2 cells
Diabetic rats were induced by a single intraperitoneal injection of 65 mg/kg of STZ dissolved in 0.1 M sodium citrate buffer (pH 4.5) after acclimation for 1 week according to our previously described method. Age matched control rats only received vehicle. On day 7 after STZ injection, fasting blood glucose levels were measured using a commercially available glucose kit (Jiancheng Biotech Co., Nanjing, China) based on the glucose oxidase method. Rats with fasting blood glucose levels in excess of 11.1 mM were considered to be diabetic. The serum of diabetic rats was collected after 5 weeks following STZ injection. The characteristics of the animals could be found in our previous report (6) . The serum was inactivated by heating at 56°C for 30 min and filtered with a 0.22mm filter before treatment. The concentrations of fatty acids (PA, OA, SA, LA, and AA) in serum were assayed as their 2nitrophenylhydrazine derivatives by reversephase HPLC previously described (14) . The linear ranges were 7.8 -1000 mg/mL (R 2 > 0.9998) and the recoveries were all above 80% for all fatty acids detected.
HepG2 cells were exposed to serum from diabetic rats, serving as an in vitro diabetic model to mimic the diabetic situation (15) . Subconfluent (approximately 80%) HepG2 cells seeded in 24well plates were incu bated in presence of 100% serum from diabetic or control rats for 48 h. The CYP3A4 activity was measured as described above. The cell viability test by MTT assay showed that 48h exposure to 100% diabetic rat serum or 100% control rat serum used in this study did not damage the viability of cultured cells.
Effects of the abnormal components in diabetic serum on CYP3A4 activity in HepG2 cells
Some components in serum are abnormal under the diabetic condition, including decreased level of insulin and increased levels of glucose, cholesterol, and fatty acids. The effects of abnormally altered components on the CYP3A4 activity in cells were investigated. Briefly, subconfluent (approximately 80%) HepG2 cells seeded in 24well plates were exposed to freeserum DMEM containing different concentrations of insulin, glucose, cholesterol, and fatty acids (PA, OA, SA, LA, and AA) for 48h. DMEM with 25 mM of glucose was used in the experiment of insulin, cholesterol, and fatty acids. DMEM without glucose was used in the experiment of glucose, and then different concentrations of glucose were added in the DMEM. The control cells were incu bated in freeserum DMEM. Cholesterol was dissolved in ethanol as a stock solution. For the control, the same volume of ethanol was added and the final concentration of ethanol was less than 0.5%. For fatty acids, the prepa ration of fatty acid and BSA complex was made accord ing to the reported method (16) . A 100 mM stock solution of each fatty acid was prepared by diluting the fatty acid in DMSO. Fatty acid was added from the stock solution bound to 100 times volume of 10% BSA dis solved in freeserum DMEM and was adjust to 10 g/L of BSA at the final concentration by adding DMEM.
The Fa2N4 cell line, an immortalized human hepato cyte, has been proved to exhibit characteristics similar to that of primary hepatocytes, particularly induction and inhibition of CYP450 enzymes. Therefore, the Fa2N4 cell line was also used to verify induction of CYP3A4 activity by PA, OA, SA, LA, and AA. The Fa2N4 cells, following 2day incubation in a 24well plate, were exposed to 0.2 mM PA, OA, SA, LA, or AA for 48 h. The medium was replaced with freshly prepared solu tions of media and fatty acids every 24 h.
Effects of pharmacological inhibitors on fatty acidinduced CYP3A4 activity in HepG2 cells
Chelerychrine (PKC inhibitor, 0.4, 2, and 10 mM), wortmannin (PI3K/Akt inhibitor; 0.4, 2, and 10 mM), Compound C (AMPK inhibitor; 2, 10, and 50 mM), and PTCD (NfkB inhibitor; 0.4, 2, and 10 mM) were used to investigate whether these inhibitors reverse the altera tion in CYP3A4 activity induced by fatty acids. HepG2 cells were incubated with 0.2 mM PA or OA, in the presence or absence of each pharmacological inhibitor for 48 h.
Western blotting
The protein expression of CYP3A4 in HepG2 cells were determined by western blotting. Homogenate pro teins (100 mg) from treated HepG2 cells were separated by sodium dodecyl sulfate-polyacrylamide (10%) gel electrophoresis and transferred onto a PVDF transfer membrane. Nonspecific binding sites were blocked with 5% (w/v) nonfat dried milk in Tween (0.1%) / phos phatebuffered saline (PBST, pH 7.4) for 2 h, and then the blots were incubated with human monoclonal antibody to CYP3A4 (1:2500; Abcam, Ltd., Hong Kong) overnight at 4°C. GAPDH (human monoclonal antibody, 1:10,000; Anbo Biotechnology Co., Ltd., San Francisco, CA, USA) was used as an internal control. After washing, membranes were incubated with peroxidase conjugated antirabbit IgG (1:2500; Bioworld Technology Co., Ltd., St. Louis Park, MN, USA) or antimouse IgG (1:10000; Cell Signaling Technology Co., Ltd., MN, USA) for 2 h and then washed 4 times with PBST. Immunoreactive proteins were visualized by chemilumi nescence (ECL Western Blotting Detection Reagents: KGP1123; Nanjing KeyGEN Biotechnology Co., Ltd., Nanjing, China), and band density was measured by densitometry.
QT-PCR analysis
For quantitative comparison of CYP3A4 and PXR mRNA levels, QTPCR was performed using SYBR green fluorescence. HepG2 cells (4.0 × 10 5 cells/well) maintained in DMEM supplemented with 10% fetal bovine serum (FBS) were seeded in 6well plates and incubated at 37°C overnight. Then the cells were incu bated with medium containing PA, OA, and positive inducer (rifampicin and VD3) for 48 h. The control cells were treated with vehicle. Total RNA was isolated from the cultured cells using the TRIzol reagent (SunShineBio, Nanjing, China) according to the manu facturer's instructions. Primers used for the amplification of the cDNAs of interest were as follows: for CYP3A4, forward 5′-CAGTTTTACCCAATAAGGCACCAC-3′ and reverse 5′-ATAATCTGAGCGTTTCATTCACCAC-3′; for PXR, forward 5′-TCAGATCCCACTAAAGTGT CAAG-3′ and reverse 5′-GACTCAGGAAGCGAA CAAAC-3′; for b-actin, forward 5′-CAGTCGGTTG GAGCGAGCAT-3′ and reverse 5′-GGACTTCCTG TAACAACGCATCT-3′. The cDNA synthesis reaction was performed from 2 mg total RNA with the Prime Script TM RT Reagent Kit. mRNA expression was normal ized against that of bactin. TaqMan real time PCR assays were performed on a PTC200 Thermo Cycler (MJ Research, Waltham, USA). Amplification was performed in 25 mL reaction mixture: 12.5 mL of qPCR Master Mix (Promega, Madison, WI, USA), 2.0 mL of 10 × cDNA, 2.5 mL of 2 mM forward and reverse primers, and 9.5 mL of Nucleasefree water. Each assay was performed in triplicate with bactin mRNA as the endogenous control. The QTPCR thermal cycling parameters were as follows: initial denaturation for 2 min at 95°C, followed by 40 cycles of 95°C for 5 s and 60°C for 30 s. Melting curves were performed to investigate the specificity of the PCR reaction. Relative quantification (RQ) of each gene expression was calculated according to comparative Ct method using the formula:
Statistical analysis
All data were expressed as the means ± standard devia tion (S.D.). Analysis of variance (ANOVA) was used to determine if the differences between the experimental groups were statistically significant. The 0.05 level of probability was used as the criteria for significance.
Results

Activity of CYP3A4 and its induction in HepG2 cells
To assess the utility of the HepG2 cells and identify the function of CYP3A4, the activity of CYP3A4 was measured using the formation of norverapamil following 48h incubation in presence of the inducers (VD3 and rifampicin) or the inhibitors (ketoconazole and erythro mycin). Preliminary experiments showed that the forma tion of norverapamil in HepG2 cells was dependent on both the concentration of verapamil and time of incuba tion. Therefore, the concentration of verapamil and incubation time were set to 100 mM and 120 min, respec tively, for evaluating the CYP3A4 activity. As expected, both CYP3A4 inducers VD3 (0.25 and 0.5 mM) and rifampicin (10 and 20 mM) concentrationdependently increased the formation of norverapamil in HepG2 cells (Fig. 1A) . Treatments with 0.25 and 0.5 mM of VD3 led to significant increase in the CYP3A4 activity in HepG2 cells by 1.6 and 2.2fold of control cells. A significant concentrationdependent increase in CYP3A4 activity was also observed in HepG2 cells treated with rifampicin. It was also found that both CYP3A4 inhibitors ketocon azole (5 and 20 mM) and erythromycin (5 and 20 mM) significantly reduced the CYP3A4 activity in HepG2 cells (Fig. 1B) . All the results clearly demonstrated that the HepG2 cells used in the study were suitable for assessing the activity of CYP3A4. Fig. 1 . Effects of CYP3A4 inducers, inhibitors, and diabetic rat serum on CYP3A4 activity in HepG2 cells. Cells were incubated in DMEM containing of VD3 (A), rifampin (A), ketoconazole (B), or erythromycin (B) for 48 h, and then the CYP3A4 activity was detected by the formation of norverapamil. Cells were incubated in 100% serum from control rats (CON) or diabetic rats (DM) (C) for 48 h, and then the CYP3A4 activity was detected by the formation of norverapamil. Data are reported as the means ± S.D. from 4 indepen dent experiments. *P < 0.05, **P < 0.01.
Effect of serum from diabetic rats on CYP3A4 activity in HepG2 cells
The CYP3A4 activity in HepG2 cells treated with serum from diabetic rats was assessed using formation of norverapamil from verapamil (Fig. 1C) . The results showed that the 48h incubation with serum from diabetic rats significantly increased CYP3A4 activity in HepG2 cells, causing it to increase by 83% of that incubated with serum from control rats, inferring exis tence of some abnormal components inducing CYP3A4 activity in the serum of diabetic rats.
Effects of the abnormal components in diabetic serum on CYP3A4 activity in HepG2 cells
It is generally accepted that diabetes is associated with a decreased level of insulin and increased levels of glucose and cholesterol. In addition, the increased concentrations of free fatty acids in serum often occur. In this study, the concentrations of OA, LA, PA, SA, and AA in the serum of diabetic rats were also measured. It was consistent with our expectation that diabetes significantly increased the concentrations of fatty acids in serum (OA: 1.347 ± 0.397 mM in diabetic rats vs. 0.298 ± 0.088 mM in control rats, P < 0.01; LA: 0.764 ± 0.300 mM in diabetic rats vs. 0.216 ± 0.064 mM in control rats, P < 0.01; PA: 0.871 ± 0.384 mM in diabetic rats vs. 0.370 ± 0.083 mM in control rats, P < 0.05; SA: 1.103 ± 0.950 mM in diabetic rats vs. 0.315 ± 0.033 mM in control rats, P < 0.01; and AA: 0.185 ± 0.023 mM in diabetic rats vs. 0.152 ± 0.016 mM in control rats, P < 0.05).
To identify whether the induction of CYP3A4 activity results from the abnormal alteration in levels of insulin, glucose, cholesterol, or fatty acids, effects of these components on the CYP3A4 activity in HepG2 cells were screened. Contrary to our expectation, both insulin and cholesterol showed little effect on CYP3A4 activity in HepG2 cells (Fig. 2A) . In contrast, high glucose decreased the CYP3A4 activity ( Fig. 2A) . However, PA, OA, SA, and LA increased the CYP3A4 activity in HepG2 cells in a concentrationdependent manner. Fortyeight hour incubation with 0.2 mM of PA, OA, SA, and LA led increased norverapamil formation by 24%, 36%, 57%, and 44% of control cells, respectively (Fig. 2B) . Induction of CYP3A4 activity in HepG2 cells by both PA and OA was further verified using the formation of 1′-hydroxylmidazolam from midazolam (Fig. 2C) . Effects of AA on CYP3A4 activity were also investigated, and we found that incubation with 0.2 mM AA did not induce CYP3A4 activity (data not shown). All these results indicated that the increased levels of certain fatty acids in serum of diabetic rats may be one of the main factors inducing activity of CYP3A4 under diabetic state.
The effects of 4 fatty acids on CYP3A4 activity were further verified using Fa2N4 cells (Fig. 2D) . Similar to the findings in HepG2 cells, 48h incubation with 0.2 mM of PA, OA, SA, and LA enhanced CYP3A4 activity in Fa2N4 cells.
Effects of PA and OA on protein and mRNA expression of CYP3A4 in HepG2 cells
Accumulated evidences showed that unsaturated fatty acid and saturated fatty acids may have different, some times opposite, biochemical or physiological activity or effect. Therefore, we chose OA and PA as representa tives of unsaturated fatty acid and saturated fatty acid, respectively, to further study their effects on the induction of CYP3A4 activity. Effects of PA and OA on protein and mRNA expression of CYP3A4 in HepG2 cells were measured by western blotting and QTPCR, respectively (Figs. 3 and 4) . As expected, OA and PA both increased protein and mRNA expressions of the CYP3A4 in HepG2 cells. PA induction on protein and mRNA expressions of CYP3A4 was stronger than that of OA. VD3 and rifampicin, positive inducers of CYP3A4, also strongly induced protein and mRNA expression of CYP3A4. Nuclear receptor pregnane X receptor (PXR) is considered to be a key regulator of CYP3A4 gene transactivations triggered by chemicals. The present results showed that both OA and PA also markedly enhanced mRNA expression of PXR in HepG2 cells.
Effects of pharmacological inhibitors on fatty acidinduced CYP3A4 activity in HepG2 cells
To determine which cell signaling pathways were involved in the fatty acids-mediated induction of CYP3A4 activity, HepG2 cells were incubated with 0.2 mM PA or OA coadministrated with different pharma 5 mM) , or rifampicin (RIF, 10 mM) for 48 h. Total RNA was isolated, reversely transcribed, and subjected to TaqMan real time PCR. The mRNA expressions were normalized to bactin and presented as relative folds over vehicle controls. Data are reported as the means ± S.D. from 4 independent experiments. *P < 0.05, **P < 0.01. cological inhibitors, including chelerychrine (PKC in hibitor), wortmannin (PI3K/Akt inhibitor), Compound C (AMPK inhibitor), and PTCD (NfkB inhibitor) (Fig. 5) . The CYP3A4 activity was evaluated by the metabolism of midazolam. It was interesting to find that the NfkB inhibitor PTDC enhanced PAmediated induction of CYP3A4 activity in a concentrationdependent manner, while attenuating the OAmediated induction of CYP3A4 activity. Compound C concentrationdependently inhib ited both OA and PA inductions of CYP3A4 activity. The activities of CYP3A4 in cells cotreated with 10 mM compound C were only 34% and 71% of cells treated only with PA and OA, respectively. Chelerythrine dose dependently inhibited the OAmediated induction of CYP3A4 activity. However, only low concentration of chelerythrine (0.2 mM) could suppress PAmediated induction of CYP3A4 activity. Wortmannin hardly affected PAmediated induction of CYP3A4 activity. Although Wortmannin showed a trend to affect OA mediated induction of CYP3A4 activity, no concentra tiondependent manner was observed.
Effects of the pharmacological inhibitors themselves on CYP3A4 activity were also investigated. The results demonstrated that most pharmacological inhibitors with the concentration used could not alter the CYP3A4 activity, but the high concentrations of Compound C (10 mM), chelerythrine (5 mM), and wortmannin (10 mM) significantly influenced the CYP3A4 activity. Significant increases of CYP3A4 activity were observed in 5 mM chelerythrine-treated cells and 10 mM wortmannintreated cells. However, 10 mM Compound C caused a decrease in the CYP3A4 activity of HepG2 cells. 
Discussion
Our previous studies showed that activity and expres sion of the hepatic CYP3A in diabetic rats were signifi cantly upregulated, leading to the smaller AUC and higher clearance of verapamil, the substrate of CYP3A4 (6, 7). The present study was designed to identify factors leading to induction of hepatic CYP3A4 activity under the diabetic condition using HepG2 cell lines as an in vitro model. The activity of hepatic CYP3A4 was evaluated using formation of norverapamil from vera pamil and 1′-OH midazolam from midazolam. The main finding was that serum from diabetic rats significantly increased hepatic CYP3A4 activity. Further studies showed that the induction was attributed to the increased concentrations of free fatty acids in serum.
Primary human hepatocytes are considered to be the gold standard model for xenobiotic metabolism, but large interindividual donor variability, rapid loss of drug metabolizing enzyme expression, poor availability, and high cost have limited its application (17, 18) . Several human hepatic cell lines (e.g., HepG2, LS180, Fa2N4, and HepaRG) have been introduced to overcome the previously mentioned drawbacks despite the lower constitutive levels of drugmetabolizing enzymes in these cell lines relative to human hepatocytes. The HepG2 cell line is one of the most widely used human hepatoma cells. HepG2 cells possess both phase I and II enzymes, and it has been verified as an in vitro model to assess the induction of CYP3A4 activity by several studies (19 -22) . But the activity of this enzyme is dependent on the source and culture conditions (23) . Therefore, HepG2 cells routinely used in assays in vitro should be firstly characterized for their drugmetaboliz ing capabilities. At the beginning of this study, the activity of hepatic CYP3A4 was confirmed using two probe substrates of CYP3A4, verapamil and midazolam. The activity of hepatic CYP3A4 could be both induced by CYP3A4 inducers (rifampicin and VD3) and inhibited by CYP3A4 inhibitors (ketoconazole and erythromycin). All these results clearly demonstrated that the HepG2 cell line used in the study was suitable for assessing of hepatic CYP3A4 activity.
Diabetic serum-treated cells were widely used to investigate the impact of diabetes on cells in vitro, including rabbit aortic myomedial cells (24) , rat embryos (25) , and human endothelial cells (26) . We also used the cocultured rat brain microvessel endothelial cell monolayers with 100% diabetic rat serum as in vitro diabetic model to examine the effect of the diabetes on the function of Pglycoprotein (15) and breastcancer resistance protein (27) in the blood-brain barrier. Here, HepG2 cells were cocultured with 100% diabetic serum as in vitro diabetic model to investigate effects of serum from diabetic rats on hepatic CYP3A4 activity. As expected, the incubation with serum from diabetic rats significantly increased CYP3A4 activity, inferring the existence of some components inducing CYP3A4 activity.
It is generally accepted that diabetes, apart from the decreased level of insulin and increased level of glucose in serum, is also associated with increased levels of cholesterol and fatty acids. In order to investigate whether alterations in these components contribute to induction of CYP3A4 activity, the effects of these components on CYP3A4 activity in HepG2 cells were studied separately. It was found that cholesterol had little influence on the activity of CYP3A4. In addition, insulin treatment was reported to reverse the alteration in hepatic CYP450s induced by diabetes (28) , and absence of insulin led to a dramatic decrease in the levels of CYP2E1 and CYP2B mRNA and protein level in primarily cultured rat hepatocytes. However, data from the present study showed that insulin itself did not affect hepatic CYP3A4 activity, which was in agreement with Woodcroft's report in primarily cultured rat hepato cytes (29) . Similarly, Woodcroft et al. reported that absence of insulin attenuated induction of phenobarbital induced CYP3A in hepatocytes (30) . In terms of the contribution of glucose, we discovered that physiological or pathological levels of glucose (5.5, 25 mM) failed to affect the activity of CYP3A4 in HepG2 cells, while a much higher glucose level (68 mM) reduced CYP3A4 activity in HepG2 cells without affecting the cell viability (31) , inferring that induction of CYP3A4 did not result from the increased level of glucose. Several studies have showed that consumption of glucose or high carbo hydrate diet decreased metabolism of some drugs such as barbiturates, antipyrine, and theophylline (32, 33) . In vitro, coculture with high glucose (25 mM) also reduced CYP450 enzyme activity in endothelial cells via elevat ing level of superoxide (34) . All these results indicated that alterations in levels of insulin, cholesterol, and glucose seemed not to be main factors inducing hepatic CYP3A4 activity in serum from diabetic rats.
Altered level of serum free fatty acids occurs in numerous diseases related to abnormal lipid metabo lisms, including diabetes, obesity, and nonalcoholic fatty liver disease. Our current research discovered that the concentrations of OA, LA, PA, and SA in serum of diabetic rats were several times higher than those in normal rats. Several studies have showed that the unsaturated fatty acids, not saturated fatty acids, inhibited CYP3A4catalyzed metabolic reactions (35, 36) . It was reported that 14h treatment with a highconcentration fatty acids mixture (1 and 2 mM) significantly decreased CYP3A4 activity in primarily cultured human hepato cytes (37) . However, data from the present study showed that 48h treatment of hepatic cells (both HepG2 and Fa2N4 cells) with PA and OA (0.1 and 0.2 mM) induced CYP3A4 activity. The discrepancy may result from different incubation time and concentration of fatty acids being used. High concentration of fatty acids was reported to induce the accumulation of lipids and apoptosis in hepatocytes (38) . Our preliminary study also showed that fatty acid at higher than 0.2 mM could significantly decrease the cell viability after 48h treatment (data not shown). It was reported that the impact of diabetes on CYP450 also has a relationship with the duration of the disease, and longterm diabetes resulted in more significant changes of CYP450 (39, 40) . These findings indicated that treatment of cells with a high level of fatty acids for long time may be better for investigating the effect of fatty acids in an in vitro study. It was also found that that the expressions of CYP3A4 and PXR mRNA in HepG2 cells could be induced by both PA and OA, and induction of CYP3A4 by chemical agents is usually via activating PXR, inferring that induction of CYP3A4 by fatty acids may be involved in PXR. All the results suggested that induction of CYP3A4 activity was, at least in part, due to the increased levels of fatty acids in the serum of diabetic rats. Our previous studies showed the expression and activity of CYP3A2 were increased in the liver of type 2 diabetic rats and rats fed with highfat diet (7). Irizar et al. also reported that CYP3A level was higher in the obese Zucker rat when compared with the lean littermate (41) . In the liver of rats with nonalcoholic steatohepatitis, CYP3A11 was significantly enhanced (42) , but the CYP3A was reduced in rats with non alcoholic fatty liver disease (43) . The above studies demonstrated that lipid metabolism disorders could alter the activity and expression of CYP3A4. Besides fatty acid, there are many other abnormal factors in diabetic serum such as ketone body and hormones (growth hormone and testosterone levels). It has been reported that ketone body increased the expression of CYP2B in primary cultured rat hepatocytes (44) , and the elevation of ketone body plays a critical role in the upregulation of hepatic CYP2E1 in diabetic rats (45) . Impaired secretion of growth hormone in diabetic rats was also responsible for the regulation of CYP450. Testosterone replacement treatments could significantly reverse the changes in some CYP450 isoforms in the diabetic male rats (46) . Hepatic CYP2E1 increased in male rat treated by hypophysectomy, and administration of growth hormone to these rats reversed the elevated hepatic CYP2E1 (9) . These factors may also be involved in induction of CYP3A4 activity and need further study.
To study mechanisms by which free fatty acids cause CYP3A induction, we investigate the role of several signalling pathways on the CYP3A regulation, such as PI3K, AMPK, PKC, and NFkB, which have been reported to participate in the fatty acid-mediated regula tion (47 -51) . The PI3K inhibitor, wortmannin, amelio rated the insulinmediated decrease in CYP2E1 mRNA level (30, 52) , inferring PI3K as an obligatory component in the suppression of CYP2E1 expression by insulin. Similarly, both the PI3K and PKC inhibitor also amelio rated the suppressive effect of acetoacetate on CYP2E1 mRNA expression (53) . There was a report showing that NFkB plays a pivotal role in the regulation of CYP3A4 through interactions of NFkB with the PXRretinoid X receptor (RXR) complex (54) or the impact on CYP3A4 protein stability (55) . Moreover, fatty acid-induced muscle insulin resistance and glucose uptake dysfunction were involved in PKC activation and oxidative stressactivated signaling pathways (56) . All the results suggested that these signal pathways may be involved in the induction of CYP3A4 by fatty acids in HepG2 cells. To verify the deduction, the effects of these pharmaco logical inhibitors on induction of CYP3A4 in HepG2 cells by OA and PA were documented. The results showed that effects of these pharmacological inhibitors on induction of CYP3A4 by OA were different from those by PA. The inhibitors of PKC (chelerychrine) ameliorated the induction of CYP3A4 by PA and OA, showing stronger inhibition on induction of CYP3A4 activity by PA. The inhibitor of NFkB (PTDC) enhanced induction of CYP3A4 activity by PA, while it inhibited that by OA. The PI3K inhibitor (wortmannin) hardly affected induction of CYP3A4 by PA. Several studies demonstrated that PA and OA induced both NFkB (57, 58) and PKC activities (59, 60) , and the stimulatory effects of OA on the PKC pathway was stronger than those of PA (61, 62) . PA was also reported to inhibit phosphorylation of AMPK (63, 64) and Akt (65, 66) . In sharp contrast, OA enhanced the activity of Akt (67) and showed weak inhibition on phosphorylation of AMPK (68) . All these may explain why that effects of these pharmacological inhibitors on the induction of CYP3A4 by OA were different from those by PA. In light of the above, our present study provided direct evidence that induction of CYP3A4 activity by OA may be partly via AMPK, PKC, and NFkB-dependent pathways, and the induction by PA was possibly associated with a PKCdependent pathway. The real relationship between the signal pathways and the induction of CYP3A4 activity by PA and OA is still obscure and requires further investigation.
In conclusion, the present study clearly demonstrated that the increased levels of fatty acids in serum from diabetic rats contributed to induction of CYP3A4 expres sion and activity in hepatic cells, which was one of the factors leading to the upregulation of CYP3A4 in diabetic conditions. In addition, the signaling pathways participating in the regulation of CYP3A4 by PA (saturated fatty acid) may be different from that by OA (unsaturated fatty acid).
